Citi: Raises HUTCHMED (00013.HK) target price to HK$43.2, lists it as new top pick

Citi released a research report stating that the bank held an expert meeting with the principal investigators of SANOVO on November 5, further reinforcing its positive view on the potential of savolitinib in EGFR-mutant non-small cell lung cancer in the first-line setting and after osimertinib treatment, maintaining a "Buy/High Risk" rating, and adding HUTCHMED (00013.HK) as a new top pick, raising the target price from HK$40.1 to HK$43.2.